1 citations
,
August 2022 in “Медицинский совет” This study reported that among patients aged 19 to 60 who experienced hair loss after COVID-19, a treatment involving a complex drug and peptide lotion led to hair improvement in 92% of cases, with good tolerability and no reported side effects.
3 citations
,
April 2022 in “Clinical, Cosmetic and Investigational Dermatology” This review discusses evidence-based complementary strategies for enhancing hair regrowth after post-COVID-19 telogen effluvium and reports no new clinical results.
7 citations
,
May 2022 in “The Journal of Dermatology” This narrative review found that post-COVID-19 hair loss, particularly telogen effluvium, poses a significant mental and social burden, with minoxidil potentially aiding recovery, although more clinical research is needed to confirm its effectiveness.
April 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” This article reviews evidence-based complementary strategies to enhance hair regrowth after post-COVID-19 telogen effluvium, emphasizing psychological support, patient education, nutrition, and both topical and injectable hair growth stimulators.
7 citations
,
September 2020 in “Journal of Cosmetic Dermatology” This study analyzed trends in consumer and physician interest in nonsurgical hair loss therapies, finding that internet searches for treatments like minoxidil and low-level laser therapy increased over time, influenced by regulations and social media.